• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.42
  • VXN 17.07
  • VXO 11.36
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

ENZ (Enzo Biochem Inc. ($0.01 Par Value))
Last Trade 3.81 Dividend/Share 0 PE Ratio -76.2
Date September 25-2018 Dividend Yield 0.000 Return on Assets -4.21
Change 0 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -0.04 Price/Sale 2.275
Ask 0 LatestEPS Date 2017-07-31 Price to Book 2.1
Volume 0 EPS ttm -0.05 Institutional % 65.2
Avg Volume 0.13M Shares Outstanding 47.17M Insider % 14.2
Open 3.86 Float 40.46M Short Ratio 8.210
Prev Close 3.81 Return On Equity -5.1 5 Year Change % 0.500
High 3.96 Consensus EPS 0 2 Year Change % -0.250
Low 3.81 No. of Estimate 0.000 1 Year Change % -0.643
52 Week High 11.49 EPS Surprise $ null YTD Change % -0.538
52 Week Low 3.8 EPS Surprise Percent 0 6 Month Change % -0.333
52 Week Change -64.259 EBITDA 0.45M 3 Month Change % -0.282
50 Day MA 4.4376 Revenue 55.85M 1 Month Change % -0.138
200 Day MA 6.1376 Gross Profit 24.63M 5 Day Change % -0.132
Market Cap 179.7M Cash 131.02M 30 Day Change % -0.075
Beta 1.071362 Debt 0.57M Stock Exchange New York Stock Exchange
Sector Healthcare Revenue Per Share 1 Short Interest 0.9M
Short Date 2018-08-31 Revenue Per Employee 118320 Short Ratio 8.210
Company Profile

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.